Systematic therapy for unresectable or metastatic soft-tissue sarcomas: Past, present, and future

Sherif S. Morgan, Lee D Cranmer

Research output: Contribution to journalArticle

8 Scopus citations


Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.

Original languageEnglish (US)
Pages (from-to)331-349
Number of pages19
JournalCurrent Oncology Reports
Issue number4
Publication statusPublished - Aug 2011



  • Chemotherapy
  • Metastatic soft-tissue sarcoma
  • Sarcoma
  • Systemic therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this